MaxCyte, Inc. (NASDAQ:MXCT) Given Consensus Rating of “Hold” by Brokerages

Shares of MaxCyte, Inc. (NASDAQ:MXCT) have received a consensus recommendation of “Hold” from the five research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $5.50.

A number of brokerages have weighed in on MXCT. Weiss Ratings raised shares of MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 24th. Craig Hallum lowered their price objective on shares of MaxCyte from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, March 25th. Finally, Wall Street Zen upgraded shares of MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday, May 16th.

MaxCyte Price Performance

NASDAQ MXCT opened at $1.28 on Friday. The firm has a market cap of $137.12 million, a P/E ratio of -3.46 and a beta of 1.47. The stock’s 50-day moving average is $1.11 and its 200-day moving average is $1.02. MaxCyte has a one year low of $0.64 and a one year high of $2.37.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.06. MaxCyte had a negative return on equity of 20.03% and a negative net margin of 121.16%.The business had revenue of $6.22 million during the quarter, compared to analyst estimates of $7.28 million. Equities analysts anticipate that MaxCyte will post -0.29 EPS for the current year.

Institutional Trading of MaxCyte

Several hedge funds and other institutional investors have recently modified their holdings of MXCT. Prudential Financial Inc. acquired a new position in shares of MaxCyte during the second quarter worth about $26,000. State of Wyoming acquired a new stake in MaxCyte in the 2nd quarter valued at approximately $38,000. Jain Global LLC acquired a new stake in MaxCyte in the 4th quarter valued at approximately $45,000. BNP Paribas Financial Markets lifted its stake in MaxCyte by 39.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock valued at $57,000 after acquiring an additional 10,263 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in MaxCyte in the 4th quarter valued at approximately $67,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.